64 related articles for article (PubMed ID: 26357881)
1. Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.
Chen YJ; Makin C; Bollu VK; Navaie M; Celli BR
J Med Econ; 2016; 19(1):11-20. PubMed ID: 26357881
[TBL] [Abstract][Full Text] [Related]
2. Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol.
Ganapathy V; Stensland MD
Int J Chron Obstruct Pulmon Dis; 2017; 12():1793-1801. PubMed ID: 28694692
[TBL] [Abstract][Full Text] [Related]
3. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.
Celli BR; Navaie M; Xu Z; Cho-Reyes S; Dembek C; Gilmer TP
Int J Chron Obstruct Pulmon Dis; 2019; 14():1019-1031. PubMed ID: 31190787
[No Abstract] [Full Text] [Related]
4. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.
Bollu V; Ernst FR; Karafilidis J; Rajagopalan K; Robinson SB; Braman SS
Int J Chron Obstruct Pulmon Dis; 2013; 8():631-9. PubMed ID: 24353413
[TBL] [Abstract][Full Text] [Related]
5. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.
Donohue JF; Bollu VK; Stull DE; Nelson LM; Williams VS; Stensland MD; Hanania NA
Int J Chron Obstruct Pulmon Dis; 2018; 13():499-508. PubMed ID: 29440887
[TBL] [Abstract][Full Text] [Related]
6. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.
Donohue JF; Hanania NA; Make B; Miles MC; Mahler DA; Curry L; Tosiello R; Wheeler A; Tashkin DP
Chest; 2014 Dec; 146(6):1531-1542. PubMed ID: 25451347
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat
Koch A; Watz H; Maleki-Yazdi MR; Bothner U; Tetzlaff K; Voß F; McGarvey L
NPJ Prim Care Respir Med; 2017 Oct; 27(1):60. PubMed ID: 29061968
[TBL] [Abstract][Full Text] [Related]
8. Role of arformoterol in the management of COPD.
King P
Int J Chron Obstruct Pulmon Dis; 2008; 3(3):385-91. PubMed ID: 18990965
[TBL] [Abstract][Full Text] [Related]
9. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
[TBL] [Abstract][Full Text] [Related]
10. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population.
Coutinho AD; Lokhandwala T; Boggs RL; Dalal AA; Landsman-Blumberg PB; Priest J; Stempel DA
Int J Chron Obstruct Pulmon Dis; 2016; 11():1223-31. PubMed ID: 27354781
[TBL] [Abstract][Full Text] [Related]
11. Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population.
Davis JR; Wu B; Kern DM; Tunceli O; Fox KM; Horton J; Legg RF; Trudo F
Am Health Drug Benefits; 2017 Apr; 10(2):92-102. PubMed ID: 28626506
[TBL] [Abstract][Full Text] [Related]
12. β
Arif E; Medunjanin D; Solanki A; Zuo X; Su Y; Dang Y; Winkler B; Lerner K; Kamal AI; Palygin O; Cornier MA; Wolf BJ; Hunt KJ; Lipschutz JH
Am J Physiol Renal Physiol; 2024 Jan; 326(1):F20-F29. PubMed ID: 37916289
[TBL] [Abstract][Full Text] [Related]
13. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis.
Abudagga A; Sun SX; Tan H; Solem CT
Int J Chron Obstruct Pulmon Dis; 2013; 8():175-85. PubMed ID: 23589684
[TBL] [Abstract][Full Text] [Related]
14. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data.
Mapel DW; Dutro MP; Marton JP; Woodruff K; Make B
BMC Health Serv Res; 2011 Feb; 11():43. PubMed ID: 21345188
[TBL] [Abstract][Full Text] [Related]
15. Impact of antiviral therapy on short- and long-term outcomes of patients with chronic obstructive pulmonary disease after influenza infection.
Wallick C; To TM; Korom S; Masters H; Wu N; Moawad D; Hanania NA
Influenza Other Respir Viruses; 2023 Dec; 17(12):e13231. PubMed ID: 38098649
[TBL] [Abstract][Full Text] [Related]
16. Quantifying the Length of Stay and Economic Impact of Albuterol and Levalbuterol in Hospitalized Patients With Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study.
Liu X; Zhang H; Yang Z; Ran Y; Qiu Y; Wang L; Zeng L; Li X; Zhi C; Lu J
Cureus; 2024 Apr; 16(4):e59039. PubMed ID: 38803713
[TBL] [Abstract][Full Text] [Related]
17. Inhaler Formulary Change in COPD and the Association with Exacerbations, Health Care Utilization, and Costs.
Duan KI; Donovan LM; Spece LJ; Wong ES; Feemster LC; Bryant AD; Plumley R; Crothers K; Au DH
Chronic Obstr Pulm Dis; 2024 Jan; 11(1):37-46. PubMed ID: 37931593
[TBL] [Abstract][Full Text] [Related]
18. Asthma Patients Benefit More Than Chronic Obstructive Pulmonary Disease Patients in the Coronavirus Disease 2019 Pandemic.
Xiong R; Zhao Z; Lu H; Ma Y; Zeng H; Chen Y
Front Med (Lausanne); 2021; 8():709006. PubMed ID: 34568369
[No Abstract] [Full Text] [Related]
19. The effects of theophylline on hospital admissions and exacerbations in COPD patients: audit data from the Bavarian disease management program.
Fexer J; Donnachie E; Schneider A; Wagenpfeil S; Keller M; Hofmann F; Mehring M
Dtsch Arztebl Int; 2014 Apr; 111(17):293-300. PubMed ID: 24828099
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
